Symbol | Exchange | Currency |
|---|
e-therapeutics PLC (LON:ETX) said it has passed a key landmark in its collaboration with drug discovery group Galapagos that triggers a milestone payment under its pre-clinical and...
e-therapeutics PLC (LON:ETX) said it has passed a key landmark in its collaboration with drug discovery group Galapagos that triggers a milestone payment under its pre-clinical and...
Drug discovery group e-therapeutics PLC (LON:ETX) has appointed Alison Gallafent as its head of intellectual property. A UK-chartered patent attorney and European patent attorney,...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 38.25 | 38.25 | 38.25 | -0.75 | -1.92% | 181.90K | London | |||
| 133.92 | 135.30 | 133.50 | -1.04 | -0.77% | 16.30M | London | |||
| 357.60 | 361.75 | 354.35 | -1.60 | -0.45% | 28.44M | London | |||
| 1.15 | 1.15 | 1.15 | -0.0750 | -6.12% | 30.92M | London | |||
| 48.40 | 49.90 | 48.40 | -0.45 | -0.92% | 908.38K | London | |||
| 159.96 | 162.70 | 159.06 | +0.02 | +0.01% | 12.78M | London | |||
| 1.83 | 2.502 | 1.50 | 0.000 | 0.00% | 0.00 | London | |||
| 66.00 | 66.90 | 65.90 | -0.80 | -1.20% | 1.13M | London | |||
| 1,441.80 | 1,486.20 | 1,422.40 | +7.60 | +0.53% | 10.51M | London | |||
| 235.00 | 240.00 | 234.60 | -1.00 | -0.42% | 2.15M | London | |||
| 360.10 | 365.55 | 357.35 | -9.80 | -2.65% | 46.51M | London | |||
| 2,737.00 | 2,741.00 | 2,663.00 | +44.0 | +1.63% | 603.10K | London | |||
| 271.55 | 274.80 | 270.80 | -2.35 | -0.86% | 12.29M | London | |||
| 313.20 | 319.20 | 311.40 | -5.80 | -1.82% | 798.95K | London | |||
| 1,402.00 | 1,473.50 | 1,393.50 | -67.50 | -4.59% | 547.98K | London |
e-Therapeutics Plc is a United Kingdom-based company, which provides computer-based drug discovery platform. The Company uses its Network-Driven Drug Discovery (NDD) platform to develop intellectual property protected and pre-clinical drug discovery programs. The Company utilizes its biological proficiency and computer-based platform to create and analyze network models of disease processes to identify patterns of proteins. NDD enables network analysis, data mining, machine learning, artificial intelligence and optimization to match drug-like small molecules to its networks based on their potential bioactivity.